Latest Headlines

Latest Headlines

Merck wins first round in $3B-plus hep C royalty fight with Gilead

Merck & Co. scored a hepatitis C patent win against Gilead Sciences on Tuesday. And if the jury verdict stands, Merck could collect big royalties on Gilead's megablockbuster hep C drugs Sovaldi and Harvoni.

Merck enlists patients for award-winning marketing on black box allergy-fighters Ragwitek, Grastek

Marketing a drug with a black-box warning is always challenging, but even more difficult when the treatment category is already flooded with less risky and inexpensive OTC options.

Humor or fear? Merck uses both to promote shingles shot Zostavax

Are you the type of consumer motivated by fear? Or are you more likely to take action based on advice from a humorous celeb? Doesn't matter--Merck & Co., in a push to boost vaccine sales before new competition arrives, has a shingles commercial for you.

Merck's $20M-plus Harvard deal offers a lesson on the new Economics 101 of preclinical R&D;

Last fall, the folks behind Harvard's Blavatnik Biomedical Accelerator took a promising preclinical program from the lab of Matthew Shair and essentially posted a "for sale" sign on it--touting its potential for mounting a fresh line of attack on acute myeloid leukemia with a counterintuitive therapeutic strategy ready for the clinic. The move didn't escape Merck's attention.

Doctors taking a shine to biosimilars as they get experience with them

Three years ago, doctors in Europe displayed grave doubts about using biosimilars instead of branded biologics on their patients. But after a couple of years of experience with a biosimilar of Merck's Remicade (infliximab) from Hospira and Celltrion, a new report finds doctors are much more responsive to the biologic copies.

Good news, hep C drugmakers: VA stops rationing your pricey treatments

Hep C drugmakers are struggling against restrictive coverage decisions that often limit treatment to the sickest patients. But now, companies are enjoying a bright point after the Veterans Affairs Department said that it's expanding hep C treatment to all veterans.

Journal walks back 'seriously flawed' study critical of Merck's Gardasil

Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.

Merck hands top manufacturing job to Sanat Chattopadhyay

The man who helped lead Merck & Co. out of difficulties with a slew of vaccine manufacturing issues is taking the top manufacturing job at the Big Pharma company.

Sanofi, Merck to split up their long-standing vaccines JV in Europe

Sanofi Pasteur MSD, the European vaccines joint venture between pharma giants Sanofi and Merck, has been around for 22 years. But now, the pair has decided that's long enough.

Merck, Gilead wrestle in court over $3B-plus in hep C royalties

Merck & Co. isn't just battling Gilead Sciences for market share with its brand-new hepatitis C drug. It's also fighting in court for a multibillion-dollar piece of Gilead's blockbuster franchise.